Treat-to-target trials: uses, interpretation and review of concepts.
about
Hypoglycemia Event Rates: A Comparison Between Real-World Data and Randomized Controlled Trial Populations in Insulin-Treated Diabetes.Cost-effectiveness of switching to insulin degludec from other basal insulins: evidence from Swedish real-world data.Review: treat to target in rheumatoid arthritis: fact, fiction, or hypothesis?Application of clinical judgment and guidelines to achieving glycemic goals in type 2 diabetes: focus on pharmacologic therapy.Treat to target in systemic lupus erythematosus: a commentary.Cost-Effectiveness of Insulin Degludec/Insulin Aspart Versus Biphasic Insulin Aspart in Patients with Type 2 Diabetes from a Danish Health-Care Perspective.Management of chronic spontaneous urticaria (CSU): a treat to target approach using a patient reported outcome.Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-Optimizing Glycemic Control Through Titration of Insulin Glargine 100 U/mL: A Review of Current and Future Approaches with a Focus on Asian Populations.Reporting Severe Hypoglycemia in Type 1 Diabetes: Facts and Pitfalls.Relative Contribution of Fasting and Postprandial Blood Glucose in Overall Glycemic Control: Post Hoc Analysis of a Phase IV Randomized Trial.A randomized clinical trial of basal insulin peglispro vs NPH in insulin-naïve patients with type 2 diabetes: the IMAGINE 6 trial.Comparative effectiveness and safety of different basal insulins in a real-world setting.The value of fast-acting insulin aspart compared with insulin aspart for patients with diabetes mellitus treated with bolus insulin from a UK health care system perspective.
P2860
Q31046934-3E8B3A19-F3BE-41F3-A698-11B94B1538C4Q31152059-7FADA830-7DC7-4B0D-B01E-D1658B10BED0Q33577429-F90D3E67-A7F5-43E7-9AF7-CBFCB1594468Q38219485-CAF9932C-A46D-4374-8DEA-CEE5DAFD3777Q38894396-73CFDDEF-FC6F-46C9-B047-0B161290B737Q39462093-7CC5B41E-2399-4EFB-AEE6-B8F84C680852Q41507426-9048F493-6680-469A-8B44-1AE58A1B0D8EQ42703474-F88EAA20-AF03-4FD9-A354-4D87A925212EQ44615064-2F8252CA-55B7-4234-90A7-1AA0AC81D3DFQ47871150-61655C4F-CB06-4E68-BC43-B5F91450DC5DQ51244515-0472990F-60E2-40D3-9751-8AC859B74760Q51278143-A9089794-0E62-4143-A7D6-B1FDCFDE7039Q53484316-66F4C473-E57D-4186-AC8F-6C5D0D6397ECQ55431482-43E91D75-8C80-47FD-8727-60FF4EC8492B
P2860
Treat-to-target trials: uses, interpretation and review of concepts.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Treat-to-target trials: uses, interpretation and review of concepts.
@ast
Treat-to-target trials: uses, interpretation and review of concepts.
@en
Treat-to-target trials: uses, interpretation and review of concepts.
@nl
type
label
Treat-to-target trials: uses, interpretation and review of concepts.
@ast
Treat-to-target trials: uses, interpretation and review of concepts.
@en
Treat-to-target trials: uses, interpretation and review of concepts.
@nl
prefLabel
Treat-to-target trials: uses, interpretation and review of concepts.
@ast
Treat-to-target trials: uses, interpretation and review of concepts.
@en
Treat-to-target trials: uses, interpretation and review of concepts.
@nl
P2860
P921
P356
P1476
Treat-to-target trials: uses, interpretation and review of concepts.
@en
P2093
A J Garber
P2860
P304
P356
10.1111/DOM.12129
P5008
P577
2013-06-14T00:00:00Z
2014-03-01T00:00:00Z